E!10635, Eurostars, SUBERB, ATROGI AB, SU
| Reference number | |
| Coordinator | ATROGI AB |
| Funding from Vinnova | SEK 4 999 877 |
| Project duration | September 2016 - August 2019 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
The ultimate goal is a drug for the treatment of type 2 diabetes (T2D). The purpose with the project was to develop compounds suitable as clinical candidates and to engage in a collaboration with a pharmaceutical company. A candidate drug has been nominated and large scale synthesis and formulation development for toxicological and clinical studies are ongoing. Contacts with pharmaceutical companies has been established and discussions are ongoing.
Expected long term effects
From the compounds prepared during the course of the project, we have been able to identify those that fulfill the necessary criteria of a candidate drug. The expectations at the start of the project has been surpassed as a clinical candidate already has been nominated. We also obtained results that strengthens our hypothesis on why the compounds decrease the blood glucose levels in diabetics and thus are suitable for the treatment of type 2 diabetes.
Approach and implementation
Compounds were iteratively designed, synthesized and analyzed in different in vitro systems. Synthetic methodologies were developed and evaluated. Several patent applications were submitted. The most interesting compounds were evaluated in more sophisticated systems, which led to the nomination of a candidate drug that is now scaled up for toxicological studies. Contacts were established with pharmaceutical companies with an interest in type 2 diabetes, as well as with several investors.